KR102567244B1 - 암을 치료하는 조성물 및 방법 - Google Patents

암을 치료하는 조성물 및 방법 Download PDF

Info

Publication number
KR102567244B1
KR102567244B1 KR1020177000702A KR20177000702A KR102567244B1 KR 102567244 B1 KR102567244 B1 KR 102567244B1 KR 1020177000702 A KR1020177000702 A KR 1020177000702A KR 20177000702 A KR20177000702 A KR 20177000702A KR 102567244 B1 KR102567244 B1 KR 102567244B1
Authority
KR
South Korea
Prior art keywords
delete delete
inhibitor
gsk3β
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177000702A
Other languages
English (en)
Korean (ko)
Other versions
KR20170015507A (ko
Inventor
모드 에더카오위
라마찬드란 무랄리
스테펜 판돌
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Publication of KR20170015507A publication Critical patent/KR20170015507A/ko
Application granted granted Critical
Publication of KR102567244B1 publication Critical patent/KR102567244B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177000702A 2014-06-12 2015-06-12 암을 치료하는 조성물 및 방법 Active KR102567244B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011413P 2014-06-12 2014-06-12
US62/011,413 2014-06-12
PCT/US2015/035659 WO2015192078A1 (en) 2014-06-12 2015-06-12 Compositions and methods for treating cancers

Publications (2)

Publication Number Publication Date
KR20170015507A KR20170015507A (ko) 2017-02-08
KR102567244B1 true KR102567244B1 (ko) 2023-08-16

Family

ID=54834452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000702A Active KR102567244B1 (ko) 2014-06-12 2015-06-12 암을 치료하는 조성물 및 방법

Country Status (10)

Country Link
US (4) US10029997B2 (enExample)
EP (2) EP4306173A3 (enExample)
JP (2) JP6663863B2 (enExample)
KR (1) KR102567244B1 (enExample)
CN (1) CN106794175B (enExample)
AU (3) AU2015274334B2 (enExample)
CA (1) CA2950774C (enExample)
ES (1) ES2960601T3 (enExample)
MX (1) MX388409B (enExample)
WO (1) WO2015192078A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015274334B2 (en) 2014-06-12 2020-12-17 Cedars-Sinai Medical Center Compositions and methods for treating cancers
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
CN115252610B (zh) * 2020-02-26 2024-03-26 上海科技大学 质子泵抑制剂在抗冠状病毒中的应用
CN111658766A (zh) * 2020-07-06 2020-09-15 陈长宏 GSK3β及其激动剂在上皮源性恶性肿瘤治疗与康复中的应用
WO2024019667A1 (en) * 2022-07-21 2024-01-25 Agency For Science, Technology And Research Method of inhibiting epithelial-mesenchymal transition and cancer metastasis
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132153A1 (en) * 2007-04-27 2008-11-06 Æterna Zentaris Gmbh Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711492A (en) * 1970-12-08 1973-01-16 Basf Ag Thiadiazolidinediones
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
EP0948489A1 (en) * 1996-12-17 1999-10-13 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
US6045925A (en) 1997-08-05 2000-04-04 Kansas State University Research Foundation Encapsulated nanometer magnetic particles
CA2366264A1 (en) * 1999-04-02 2000-10-12 Bristol-Myers Squibb Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
HUP0304069A2 (hu) * 2001-05-11 2004-04-28 Pharmacia Corp. Aromás szulfon-hidroxamátok és proteázgátlókként való alkalmazásuk
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6676729B2 (en) 2002-01-02 2004-01-13 International Business Machines Corporation Metal salt reduction to form alloy nanoparticles
EP1339075A1 (en) 2002-02-25 2003-08-27 Motorola, Inc. Magnetic nanomaterials and synthesis method
US6878445B2 (en) 2002-03-08 2005-04-12 Fuji Photo Film Co., Ltd. Nanoparticle coated material and production method of same
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
DE10331439B3 (de) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US7812016B2 (en) * 2003-05-13 2010-10-12 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US7396589B2 (en) 2003-07-31 2008-07-08 Industrial Technology Research Institute Core-shell magnetic nanoparticles comprising an inner-transition element
TW593158B (en) 2003-07-31 2004-06-21 Ind Tech Res Inst Magnetic nanoparticle
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
GB0402496D0 (en) * 2004-02-04 2004-03-10 Argenta Discovery Ltd Novel compounds
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US7700193B2 (en) 2005-04-08 2010-04-20 Industrial Technology Research Institute Core-shell structure with magnetic, thermal, and optical characteristics and manufacturing method thereof
US20070264199A1 (en) 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
WO2007129062A1 (en) 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
CN101765585B (zh) * 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
US20100272717A1 (en) * 2007-12-13 2010-10-28 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2012012320A1 (en) * 2010-07-19 2012-01-26 Millenium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2729454B1 (en) * 2011-07-08 2015-09-16 Novartis AG Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
PL2838888T3 (pl) * 2012-02-24 2017-12-29 Asd Therapeutics Partners Llc Tiadiazolidynodiony jako inhibitory gsk-3
JP5722264B2 (ja) 2012-03-23 2015-05-20 株式会社日立ハイテクノロジーズ データ処理装置、データ容量増加抑制方法
MX364295B (es) * 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用
AU2015274334B2 (en) 2014-06-12 2020-12-17 Cedars-Sinai Medical Center Compositions and methods for treating cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132153A1 (en) * 2007-04-27 2008-11-06 Æterna Zentaris Gmbh Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STN structure search result : CAS No. 1026513-33-6 (2008.06.08.) 및 CAS No. 1061794-10-2 (2008.10.15.))*
STN structure search result: Abstract of IT362200 A*

Also Published As

Publication number Publication date
MX388409B (es) 2025-03-19
EP3154544A4 (en) 2017-12-20
JP2020090537A (ja) 2020-06-11
JP2017523141A (ja) 2017-08-17
US20210276964A1 (en) 2021-09-09
AU2021201667B2 (en) 2022-11-17
EP3154544B1 (en) 2023-08-02
CN106794175A (zh) 2017-05-31
CA2950774A1 (en) 2015-12-17
CN106794175B (zh) 2020-06-09
CA2950774C (en) 2023-03-21
EP3154544A1 (en) 2017-04-19
JP7015856B2 (ja) 2022-02-03
ES2960601T3 (es) 2024-03-05
US20180297965A1 (en) 2018-10-18
US10836735B2 (en) 2020-11-17
JP6663863B2 (ja) 2020-03-13
AU2015274334B2 (en) 2020-12-17
EP4306173A3 (en) 2024-04-10
AU2021201667A1 (en) 2021-04-08
WO2015192078A1 (en) 2015-12-17
MX2016016507A (es) 2017-04-27
US20190194152A1 (en) 2019-06-27
US10029997B2 (en) 2018-07-24
EP4306173A2 (en) 2024-01-17
KR20170015507A (ko) 2017-02-08
AU2023200895A1 (en) 2023-03-16
AU2015274334A1 (en) 2016-12-15
US10266505B2 (en) 2019-04-23
US20170121297A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
AU2021201667B2 (en) Compositions and methods for treating cancers
JP2025069232A (ja) 薬物送達のためのイオン液体
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
US11248016B2 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
CN112807434A (zh) Perk抑制剂在制备肝癌药物的增效剂中的应用
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
HK1238131B (zh) 用於治疗癌症的组合物
HK1238131A1 (en) Compositions for treating cancers
KR20250052364A (ko) 암의 치료 및/또는 예방을 위한 의약품
WO2024097972A2 (en) Compounds and methods for treating cancers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200612

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211128

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220608

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220608

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200612

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221117

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221108

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220608

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200612

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230810

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230811

End annual number: 3

Start annual number: 1

PG1601 Publication of registration